Pallas Capital Advisors LLC Has $3.05 Million Holdings in Natera, Inc. $NTRA

Pallas Capital Advisors LLC lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 26.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,307 shares of the medical research company’s stock after acquiring an additional 2,797 shares during the period. Pallas Capital Advisors LLC’s holdings in Natera were worth $3,049,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in NTRA. JPMorgan Chase & Co. boosted its stake in Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares during the period. Rakuten Investment Management Inc. bought a new position in Natera during the 3rd quarter worth about $34,096,000. New York State Common Retirement Fund raised its stake in shares of Natera by 63.2% in the 3rd quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock valued at $23,863,000 after purchasing an additional 57,400 shares during the period. SWS Partners raised its stake in shares of Natera by 11.8% in the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after purchasing an additional 4,980 shares during the period. Finally, Vontobel Holding Ltd. lifted its holdings in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 85,299 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $230.72, for a total transaction of $19,680,185.28. Following the sale, the chief executive officer owned 127,881 shares in the company, valued at $29,504,704.32. This represents a 40.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Solomon Moshkevich sold 23,205 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider directly owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 318,344 shares of company stock worth $74,091,416 over the last 90 days. Company insiders own 5.63% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the subject of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Citigroup started coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $253.47.

Natera Price Performance

Shares of NASDAQ NTRA opened at $182.65 on Friday. The business has a 50-day moving average of $211.01 and a 200-day moving average of $208.38. The stock has a market capitalization of $25.89 billion, a price-to-earnings ratio of -119.38 and a beta of 1.65. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the prior year, the company posted ($0.41) earnings per share. On average, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.